Jaguar Animal Health (NASDAQ:JAGX – Get Free Report) and Centessa Pharmaceuticals (NASDAQ:CNTA – Get Free Report) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, analyst recommendations, valuation, profitability, earnings and risk.
Institutional and Insider Ownership
12.0% of Jaguar Animal Health shares are held by institutional investors. Comparatively, 82.0% of Centessa Pharmaceuticals shares are held by institutional investors. 7.5% of Jaguar Animal Health shares are held by company insiders. Comparatively, 7.1% of Centessa Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Earnings and Valuation
This table compares Jaguar Animal Health and Centessa Pharmaceuticals”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Jaguar Animal Health | $11.69 million | 0.20 | -$38.49 million | ($33.24) | -0.02 |
| Centessa Pharmaceuticals | $6.85 million | 484.62 | -$235.76 million | ($1.83) | -13.50 |
Jaguar Animal Health has higher revenue and earnings than Centessa Pharmaceuticals. Centessa Pharmaceuticals is trading at a lower price-to-earnings ratio than Jaguar Animal Health, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Jaguar Animal Health and Centessa Pharmaceuticals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Jaguar Animal Health | -341.90% | -1,194.94% | -80.16% |
| Centessa Pharmaceuticals | N/A | -49.39% | -34.64% |
Analyst Ratings
This is a summary of current ratings and price targets for Jaguar Animal Health and Centessa Pharmaceuticals, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Jaguar Animal Health | 1 | 0 | 1 | 0 | 2.00 |
| Centessa Pharmaceuticals | 1 | 0 | 11 | 1 | 2.92 |
Jaguar Animal Health currently has a consensus target price of $60.00, suggesting a potential upside of 9,423.81%. Centessa Pharmaceuticals has a consensus target price of $38.50, suggesting a potential upside of 55.90%. Given Jaguar Animal Health’s higher probable upside, analysts clearly believe Jaguar Animal Health is more favorable than Centessa Pharmaceuticals.
Risk and Volatility
Jaguar Animal Health has a beta of 0.09, suggesting that its stock price is 91% less volatile than the S&P 500. Comparatively, Centessa Pharmaceuticals has a beta of 1.56, suggesting that its stock price is 56% more volatile than the S&P 500.
Summary
Centessa Pharmaceuticals beats Jaguar Animal Health on 10 of the 15 factors compared between the two stocks.
About Jaguar Animal Health
Jaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing plant-based prescription medicines for people and animals with gastrointestinal distress, specifically chronic and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It focuses on developing and commercializing prescription and non-prescription products for companion and production animals; and human products. The company's products include Mytesi, an anti-secretory antidiarrheal drug for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy; and Canalevia-CA1, a prescription drug product for chemotherapy-induced diarrhea in dogs. It is also developing Crofelemer, an anti-secretory antidiarrheal drug, which is in Phase 3 clinical trial for or prophylaxis of diarrhea in adult cancer patients, and to address rare/orphan disease indications, including short bowel syndrome with intestinal failure and/or congenital diarrheal disorders; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, the company is developing NP-300, a second-generation antidiarrheal drug for symptomatic relief and treatment of moderate-to-severe diarrhea. The company is headquartered in San Francisco, California.
About Centessa Pharmaceuticals
Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders. The company also develops LB101, a PD-L1xCD47 LockBody, a bi-specific monoclonal antibody for solid tumors, which is designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; and OX2R Agonists compounds are currently in development for the treatment of narcolepsy. In addition, its products pipeline comprises ORX750, an orally administered selective orexin receptor-2 (OX2R) agonist for the treatment of narcolepsy and other sleep disorders; and earlier-stage preclinical assets and discovery-stage programs. Centessa Pharmaceuticals plc was incorporated in 2020 and is headquartered in Altrincham, the United Kingdom.
Receive News & Ratings for Jaguar Animal Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jaguar Animal Health and related companies with MarketBeat.com's FREE daily email newsletter.
